Epizyme Signs its Second Major Deal of 2011
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 3 (Table of Contents)
Published: 24 Mar-2011
DOI: 10.3833/pdr.v2011.i3.1448 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In its second big pharma deal, Epizyme has formed a global partnership with Eisai to discover, develop and commercialise small molecules targeting EZH2, an epigenetic enzyme, for the potential treatment of lymphoma and other cancers in genetically defined patients...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS